CONOX

T
Timothy Webb

Primary Investigator

Overview

We hypothesize that analgesic dosing of the thoracic epidural in patients undergoing general anesthesia for major hepatobiliary surgical procedures will cause a reduction in the qNOX Index.
 
In order to investigate this hypothesis, we propose a study in which the CONOX monitor is applied to patients undergoing major hepatobiliary surgery who have received a thoracic epidural for post-operative analgesia and comparing the qNOX values of pre- and post-dosing of the thoracic epidural while under general anesthesia.  

Description

The primary objective of this study will be to determine if there is an observable reduction of the qNOX index on the CONOX monitor following analgesic dosing of a patient’s thoracic epidural in patients undergoing general anesthesia for major hepatobiliary surgery.

One secondary objective in this study will be to determine if there is any raw EEG data pattern, qCON values, and qNOX values that correlate with findings of post-operative cognitive issues following surgery (this will be evaluated in the recovery area by reviewing sedation/agitation scores).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    hepatobiliary surgery
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria:
  • ·    Qualifying procedures (non-laparoscopic):  Whipple procedures, Hepatectomies, Pancreatectomies, Biliary Reconstructions, and similar procedures.
    ·            Patients receiving a thoracic epidural for post-operative analgesia.
    ·            ASA class 1, 2, 3, or 4.
    ·            Age 18 years or older.
    ·            Male or Female.
Exclusion Criteria:
  • ·            Any patient undergoing emergency surgery.
    ·            Any patient undergoing surgery who is currently an inpatient.
    ·            Any previous diagnosis of dementia or other cognitive impairment.
    ·            Current use prior to surgery of opioid pain medications of oral morphine equivalents of 30mg daily or greater.
    ·            Contraindication to thoracic epidural placement.
    ·            Patients for whom the anesthesia team has determined cannot be safely administered 4ml of 0.25% Bupivacaine through their epidural (potentially due hemodynamic issues).

Updated on 01 May 2024. Study ID: 15776, ANES-IIR-CONOX
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center